pharma · Colon Carcinoma Metastatic in the Liver · Metastatic Melanoma · VCNX
Vaccinex
VACCINEX, INC.
Vaccinex clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1895 Mt Hope Ave, Rochester, New York 14620, US
- Employees
- 28
- Programs
- 11
- Drugs
- 8
- Patents
- 41
Vaccinex projects
4 ClinicalTrials.gov programs sponsored by Vaccinex.
Vaccinex has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Avelumab and Pepinemab
VACCINEX, INC.
Metastatic Pancreatic Adenocarcinoma
1 trial -
VX15/2503
VACCINEX, INC.
Huntington's Disease
1 trial -
VX15/2503 + avelumab
VACCINEX, INC.
Carcinoma, Non-Small-Cell Lung
1 trial -
pepinemab + pembrolizumab
VACCINEX, INC.
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
1 trial
Frequently asked questions
How many clinical projects does Vaccinex have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.